Sign In
Buy JNJ
$239.08
+7.79 (+3.37%)
At Close: Jun 23, 2026
Spravato sales momentum underscores market potential for psychedelics, atai Life Sciences seen as key beneficiary
11:42am, Friday, 18'th Jul 2025
Sales of Johnson & Johnson (NYSE:JNJ)'s esketamine nasal spray Spravato grew sequentially in the second quarter, marking a positive sign for the broader psychedelics sector, according to Jefferies an
JNJ gave us a manual on how to spot a stock that can soar after earnings, says Jim Cramer
07:47pm, Thursday, 17'th Jul 2025
'Mad Money' host Jim Cramer talks how to react when surprise stock pops happen.
Stock Of The Day: Breakout In Johnson & Johnson
04:37pm, Thursday, 17'th Jul 2025
Johnson & Johnson JNJ stalled out at resistance around the $165 level. There tends to be resistance at price levels that had previously been resistance.
Want Steady Income? 3 Top Dividend Stocks for July 2025
02:26pm, Thursday, 17'th Jul 2025
Earnings season is synonymous with market volatility. Growth-oriented investors may love trading the ups and downs, but more risk-averse investors may look for ways to generate solid returns balanced
Johnson & Johnson: The Worst Is Baked In
12:40pm, Thursday, 17'th Jul 2025
J&J's diversified business, robust pipeline, and strong free cash flow provide stability despite ongoing legal overhang from talcum powder claims. Legal risks remain a near-term headwind, but I believ
ETFs to Gain on JNJ's Solid Q1 Earnings & Upbeat Outlook
12:01pm, Thursday, 17'th Jul 2025
IHE, PPH, XLV, IYH and FTXH could gain as JNJ lifts 2025 outlook and dividend after strong Q2 earnings beat.
Johnson & Johnson Analysts Raise Their Forecasts After Upbeat Earnings
09:32am, Thursday, 17'th Jul 2025
Johnson & Johnson JNJ posted better-than-expected quarterly earnings and raised its FY2025 earnings guidance on Wednesday.
Johnson & Johnson receives U.S. FDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancer
08:00am, Thursday, 17'th Jul 2025
New Drug Application supported by results from the Phase 2b SunRISe-1 study RARITAN, N.J. , July 17, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Adm
Johnson & Johnson's Healthy 3.3%-Yielding Dividend Is a Very Safe Way to Make Passive Income
06:05am, Thursday, 17'th Jul 2025
Johnson & Johnson (JNJ 6.21%) has been an extremely reliable dividend stock for decades. The healthcare behemoth has raised its payment for 63 straight years, including by 4.8% earlier this year.
Is Johnson & Johnson a Good Dividend Stock to Buy Now?
04:37am, Thursday, 17'th Jul 2025
For decades, Johnson & Johnson (JNJ 6.21%) stock was favored by investors seeking steady gains. Looking at its post-COVID-19 performance, though, steady gains aren't what investors received.
3 Top Dividend Stocks Yielding More Than 3% That You Shouldn't Hesitate to Buy Right Now
06:01pm, Wednesday, 16'th Jul 2025
With the S&P 500 back in rally mode, the dividend yield on the broad market index is falling. It was recently down to around 1.2%, which is approaching its record low last hit a quarter-century ago.
S&P 500 Gains and Losses Today: Johnson & Johnson Stock Jumps; Universal Health Services Shares Slide
05:40pm, Wednesday, 16'th Jul 2025
Major U.S. equities indexes ticked higher Wednesday as President Donald Trump refuted reports that he is planning the immediate dismissal of Federal Reserve Chair Jerome Powell and questions about his
Johnson & Johnson (JNJ) Q2 Earnings and Revenues Top Estimates
04:26pm, Wednesday, 16'th Jul 2025
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.77 per share, beating the Zacks Consensus Estimate of $2.66 per share. This compares to earnings of $2.82 per share a year ago.
Johnson & Johnson (JNJ) Surpasses Q2 Earnings and Revenue Estimates
04:20pm, Wednesday, 16'th Jul 2025
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.77 per share, beating the Zacks Consensus Estimate of $2.66 per share. This compares to earnings of $2.82 per share a year ago.
JNJ's Stock Price Is Back in Rally Mode—The Time to Buy Is Now
04:16pm, Wednesday, 16'th Jul 2025
After years of post-COVID-19 normalization and the impact of its Kenvue spinoff, Johnson & Johnson's NYSE: JNJ stock price is back in rally mode. It is still early in the game, but the Q2 results a
